CGON

79.4702.97%
JM

James M. DeTore

Chief Financial Officer

Mr. James M. DeTore, also known as Jim, served as CFO, Treasurer & Secretary at Neurogastrx, Inc. since June 2021 to June 2025. He served as Interim Principal Financial and Accounting Officer at CG Oncology, Inc. since November 17, 2025 until April 13, 2026 and serves as its Chief Financial Officer since April 13, 2026. He served as the Chief Financial Officer and Treasurer of Proteostasis Therapeutics, Inc. since August 4, 2016 until February 10, 2017. Prior to serving at Neurogastrx, from March 2017 to May 2021, Mr. DeTore was an independent consultant providing chief financial officer services to a variety of early and mid-stage biotechnology and pharmaceutical companies. Mr. DeTore served as the Chief Financial Officer and Treasurer of bluebird bio, Inc. (Alternate Name: Genetix Pharmaceuticals Inc.) from November 2014 to February 2016. Prior to joining bluebird, he served as Vice President of Corporate Finance of Ironwood Pharmaceuticals, Inc. from February 2010 to November 2014, as Vice President of Finance from June 2006 to January 2010 and Vice President of Finance & Administration. He joined Ironwood (formerly, Microbia Inc.) in 2003. He served as Corporate Controller of Microbia, Inc., (Ironwood’s predecessor company) from October 2003 to May 2006. From May 1995 to September 2003, he held financial positions of increasing responsibility at Genzyme Corporation. In his career, he worked in corporate finance at Data General Corporation, a computer manufacturing company. Mr. DeTore earned both a B.S. in Finance and an M.B.A. from Northeastern University.

Positions